# STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update
Canonical URL: https://biopharmsignal.com/news/SSKN/strata-skin-sciences-to-report-third-quarter-2025-financial-results-on-november--9e6b9d59
Ticker: SSKN
Company: Strata Skin Sciences
Source: Strata Skin Sciences
Published: 2025-11-05 13:00 EST
## Summary

STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company...

## Article Body
STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2025 financial results on Thursday, November 13, 2025 after the market close.

STRATA management will subsequently host a conference call at 4:30 p.m. ET on Thursday, November 13, 2025 to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.

To listen to the conference call, interested parties within the U.S. should dial 1-866-524-3160 (domestic) or 1-412-317-6760 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the STRATA Skin Sciences, Inc. conference call.

The conference call will also be available through a live webcast that can be accessed at STRATA Skin Sciences Q3 2025 Earnings Webcast.

A telephonic replay of the call will be available until November 20, 2025 by dialing 1-855-669-9658 (or 1-412-317-0088 for international toll callers) and using replay access code 3125911. To access the replay using an international dial-in number, please see here.

A webcast earnings call replay will be available approximately one hour after the live call and remain accessible until May 13, 2026.

About STRATA Skin Sciences, Inc. STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC ® excimer laser, VTRAC ® lamp systems, and the TheraClear ® X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor This press release includes “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com .

Investor Contact: CORE IR 516-222-2560 IR@strataskin.com
## Recent Company News
- 2026-07-28 13:15 EST — [STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer](https://biopharmsignal.com/news/SSKN/strata-skin-sciences-appoints-medical-device-commercial-leader-erica-jordan-as-c-0c0f0fbe) — Source: Strata Skin Sciences
- 2026-05-18 12:30 EST — [New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA’s Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo](https://biopharmsignal.com/news/SSKN/new-peer-reviewed-publication-confirms-unprecedented-response-rates-for-strata-s-afe4339a) — Source: Strata Skin Sciences
- 2026-02-19 21:05 EST — [STRATA Skin Sciences Confirms Nasdaq Delisting](https://biopharmsignal.com/news/SSKN/strata-skin-sciences-confirms-nasdaq-delisting-5731a467) — Source: Strata Skin Sciences
- 2026-02-18 13:15 EST — [Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser](https://biopharmsignal.com/news/SSKN/johns-hopkins-dermatology-expands-advanced-care-for-inflammatory-and-autoimmune--33c1b6e0) — Source: Strata Skin Sciences
- 2026-02-17 13:15 EST — [STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Efficacy of 308 nm Excimer Laser for Plaque Psoriasis](https://biopharmsignal.com/news/SSKN/strata-skin-sciences-highlights-meta-analysis-confirming-clinical-efficacy-of-30-46b0403b) — Source: Strata Skin Sciences
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)